title: First description of an uterine perforation potentially imputable to treatment with bevacizumab.
authors.forename: Thomas
authors.initials: T
authors.lastname: Uguen
authors.forename: Bérengère
authors.initials: B
authors.lastname: Leconte
authors.forename: Romain
authors.initials: R
authors.lastname: Desgrippes
authors.forename: Belinda
authors.initials: B
authors.lastname: Tchoundeu
authors.forename: Jean François
authors.initials: JF
authors.lastname: Bretagne
authors.forename: Sylvain
authors.initials: S
authors.lastname: Manfredi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary*; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology*; D018450:Disease Progression; D017809:Fatal Outcome; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed; D014595:Uterine Perforation / Q000139:chemically induced* / Q000000981:diagnostic imaging
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin